FORTIS INC./ CA3495531079 /
| 11/10/2024 17:27:24 | Chg. +0.580 | Volume | Bid17:27:24 | Ask17:27:24 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 39.540EUR | +1.49% | - Turnover: - |
39.540Bid Size: - | 39.690Ask Size: - | 19.45 bill.EUR | - | - |
GlobeNewswire
06/08
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
23/07
Advisory: Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
02/07
Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
18/06
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire
10/06
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
23/05
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire
15/05
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire
24/04
Advisory: Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold...
GlobeNewswire
24/04
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire
23/04
Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On C...
GlobeNewswire
03/04
Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual an...
GlobeNewswire
02/04
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire
28/03
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire
19/03
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
